Biotech & Life Science Companies Target Emerging Markets In 2015

As competition between life science companies intensifies, traditional markets – especially those in the Unites States – are beginning to see secondary markets catch up. Suburbs are becoming more and more popular for companies as rents increase and specialized labor talent demand higher wages. Additionally, countries like Brazil, China and India are beginning to dominate relocation efforts as the global market grows.

Despite traditional premier markets such as Boston, Raleigh-Durham-Chapel Hill and San Francisco still drawing the most talent and the most money, clusters in emerging areas are poised to rapidly gain shares in generic drugs, biosimilars, medical devices and often-neglected drugs for rare conditions. According to JLL’s fourth annual Life Science Outlook Report, generic drugs alone – which stand near $45 billion – are positioned to makes leaps in global market share due to international focus on cost controls. Further, as the U.S. sees many of our known chronic conditions move to developing nations, the need for these generics grows exponentially.

Click here to read the full findings of the JLL Annual Report at Forbes.com…